Skip to main content
Clinical Trials/NCT03302026
NCT03302026
Completed
Not Applicable

A Proof-of-concept Study of Real-time fMRI Neurofeedback Training for Smoking Cessation

University of Pennsylvania1 site in 1 country46 target enrollmentJanuary 2, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Nicotine Use Disorder
Sponsor
University of Pennsylvania
Enrollment
46
Locations
1
Primary Endpoint
Smoking Lapse Paradigm
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior.

Detailed Description

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of \<25% suggesting that managing nicotine withdrawal is not sufficient. A smoker's response to smoking cues is one factor that increases risk of relapse. This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. First, we will conduct a pilot study in 12 smokers for technical development and to evaluate the feasibility of the proposed study procedures. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior. Upon successful completion of the technical development phase, we will proceed to a proof-of-concept phase, which will recruit 72 smokers to evaluate the efficacy of NFT for smoking behavior.

Registry
clinicaltrials.gov
Start Date
January 2, 2018
End Date
March 28, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Treatment-seeking smokers between the ages of 18 and 65, reporting consumption of at least 10 cigarettes per day for at least the past 6 months;
  • Planning to live in the area for at least the next month;
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form;
  • Able to communicate fluently in English (speaking, writing, and reading).

Exclusion Criteria

  • Smoking Behavior:
  • Use of chewing tobacco or snuff or cigars;
  • Current enrollment or plans to enroll in another smoking cessation program or research study in the next month;
  • Current or anticipated (within the next month) use of smoking cessation medications or nicotine replacement therapy (NRT);
  • A baseline carbon monoxide (CO) reading less than 10ppm.
  • Alcohol/Drugs:
  • Current alcohol consumption that exceeds 25 standard drinks/week;
  • Positive breath alcohol concentration test (BrAC greater than or equal to 0.01) at intake; a. Participants testing positive for breath alcohol with a reading equal to or greater than .08 (the legal driving limit) or who are visibly impaired will be instructed not to drive themselves home after the appointment. If a participant needs to use a phone to call for a safe ride home, an office telephone will be made available to the participant.
  • Medication:
  • Current use or recent discontinuation (within the past 30 days at the time of Intake) of:

Outcomes

Primary Outcomes

Smoking Lapse Paradigm

Time Frame: Study session 3 (scan day 3)

Time (sec) to first cigarette during a 50 minute monitored smoking lapse period in smoking laboratory

Secondary Outcomes

  • Cue induced brain signal change(Study session 3 (scan day 3))

Study Sites (1)

Loading locations...

Similar Trials